A Study of Evaluation rational drug use of Amoxicillin/Clavulanate and Ceftazidime injection in patient at Saohai Community Hospital Commemprating His Majesty the King 80th Birthday Anniversary

Abstract

This study aimed to evaluate rational drug use (RDU) of Amoxicillin/Clavulanate and Ceftazidime injections for patients in Saohai hospital in terms of prescribing pattern, treatment outcomes and to determine cost from inappropriate use of these drugs. The cross-sectional descriptive study design was conducted, collecting data during 1^st March to 31^st August, 2022. The sample were 78 patients who were administrated injection of Amoxicillin/Clavulanate and Ceftazidime. The research tools were the evaluation form of Amoxicillin/Clavulanate and Ceftazidime injection RDU guidelines that derived from the literatures, and guideline was approved from in house Pharmacy and Therapeutic Committee. Data were analyzed using descriptive statistic by frequency, percentage.

The study found that Amoxicillin/Clavulanate injection was prescribed to 52 patients.  Of 42 patients (80.58%) were treated without antibiotic sensitivity test and 10 patients (19.2%) were treated antibiotic based on sensitivity test. The Ceftazidime injection was prescribed to 26 patients. Of 15 patients (57.5%) were treated without antibiotic sensitivity test and 11 patients (42.3%) were treated antibiotic based on sensitivity test. Amoxicillin/Clavulanate injection was followed the indication criteria for 45 patients (86.5%). In terms of outcome treatment found 39 patients (75.0%) that were improved or cured. The cost of drug utilization not follow the guideline was 12,138 baht. Ceftazidime injection was followed the indication criteria for 20 patients (76.9%). In terms of outcome treatment found 17 patients (65.4%) that were improved or cured. The cost of drug utilization not follow the guideline was 5,562 baht within the 6 months period of study. In summary, Amoxicillin/Clavulanate and Ceftazidime injection usage in Saohai hospital is highly appropriate. However, RDU evaluations to monitor these drugs should be continued, together with information provision to physicians in order to increase the guideline adherence, to reduce drug resistance, to save cost from inappropriate drug use and to promote drug safety for patients.